Ignite Creation Date:
2024-05-05 @ 5:16 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00421811
Status:
COMPLETED
Last Update Posted:
2010-12-28
First Post:
2007-01-10
Brief Title:
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Sponsor:
Adherex Technologies Inc
Organization:
Adherex Technologies Inc
Study Overview
Official Title:
An Open-Label Multicenter Phase 12 Dose Escalation Study to Evaluate Safety Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma Adherex Protocol Number AHX-01-007
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
N-cadherin a protein involved in blood vessel cell binding and on the surface of many tumor cells is increased as cancer progresses ADH-1 blocks N-cadherin This study will test the safety and effects of the combination ADH-1 with Normothermic Isolated Limb Infusion of Melphalan in subjects with locally advanced malignant melanoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None